

Supplementary Table 1: Baseline characteristics of the SGLT2i 'clean' vs the DPP-4i 'clean' cohorts prior to and following propensity score matching.

	UNMATCHED			PROPENSITY SCORE-MATCHED		
	SGLT2i 'clean'	DPP-4i 'clean'	SMD	SGLT2i 'clean'	DPP-4i 'clean'	SMD
Days on DPP4i since diagnosis (mean (SD))	93 (276)	39 (179)	0.232	65 (230)	58 (231)	0.028
Days from diagnosis to index (mean (SD))	2,132 (900)	1,758 (948)	0.404	1,913 (958)	1,875 (980)	0.039
Ratio of days (mean (SD))	0.04 (0.11)	0.02 (0.08)	0.211	0.03 (0.09)	0.02 (0.09)	0.026
Year of DM diagnosis (%)			0.262			0.041
≤ 2009	17,604 (62.9)	28,857 (50.7)		9,760 (52.5)	9,617 (51.8)	
- 2010	2,014 (7.2)	4,833 (8.5)		1,541 (8.3)	1,449 (7.8)	
- 2011	1,633 (5.8)	4,284 (7.5)		1,311 (7.1)	1,321 (7.1)	
- 2012	1,308 (4.7)	3,585 (6.3)		1,104 (5.9)	1,125 (6.1)	
- 2013	1,226 (4.4)	3,250 (5.7)		1,048 (5.6)	994 (5.3)	
- 2014	1267 (4.5)	4236 (7.4)		1106 (6.0)	1194 (6.4)	
- 2015	1243 (4.4)	3923 (6.9)		1144 (6.2)	1186 (6.4)	
- 2016	1178 (4.2)	2900 (5.1)		1087 (5.8)	1151 (6.2)	
- 2017	507 (1.8)	1067 (1.9)		482 (2.6)	546 (2.9)	

Index year (%)			0.580			0.153
- 2014	598 (2.1)	7532 (13.2)		570 (3.1)	1081 (5.8)	
- 2015	6045 (21.6)	19474 (34.2)		4674 (25.2)	4481 (24.1)	
- 2016	12543 (44.8)	19065 (33.5)		7902 (42.5)	7145 (38.4)	
- 2017	8794 (31.4)	10864 (19.1)		5437 (29.3)	5876 (31.6)	
AMI with PCI n (%)	841 (3.0)	1,590 (2.8)	0.013	508 (2.7)	499 (2.7)	0.003
CABG surgery n (%)	352 (1.3)	616(1.1)	0.016	182 (1.0)	181 (1.0)	0.001
PCI with stenting n (%)	1,565 (5.6)	2,777 (4.9)	0.032	909 (4.9)	903 (4.9)	0.001
Chronic heart failure n (%)	1,417 (5.1)	2,984 (5.2)	0.008	799 (4.3)	788 (4.2)	0.003
Atrial fibrillation n (%)	1,507 (5.4)	4,057 (7.1)	0.072	1036 (5.6)	1034 (5.6)	<0.001
Stroke n (%)	1,113 (4.0)	2,992 (5.3)	0.061	733 (3.9)	799 (4.3)	0.018
Peripheral artery disease n (%)	978 (3.5)	2,257 (4.0)	0.025	564 (3.0)	593 (3.2)	0.009
Lower limb amputation n (%)	361 (1.3)	460 (0.8)	0.047	164 (0.9)	151 (0.8)	0.008
Cancer n (%)	1,872 (6.7)	5,178 (9.1)	0.089	1,297 (7.0)	1,305 (7.0)	0.002
COPD n (%)	1,441 (5.2)	2,879 (5.1)	0.004	900 (4.8)	862 (4.6)	0.010
Severe hypoglycemia n (%)	64 (0.2)	103 (0.2)	0.011	33 (0.2)	30 (0.2)	0.004
Keto-lactic acidosis n (%)	63 (0.2)	43 (0.1)	0.039	21 (0.1)	22 (0.1)	0.002
Major bleeding n (%)	538 (1.9)	1,212 (2.1)	0.015	328 (1.8)	348 (1.9)	0.008
Metformin n (%)	14,626 (52.3)	30,862 (54.2)	0.039	9,764 (52.5)	9,741 (52.4)	0.002

Sulfonylurea n (%)	10,375 (37.1)	29,801 (52.3)	0.311	8,979 (48.3)	8,931 (48.1)	0.005
GLP-1RA n (%)	2,693 (9.6)	917 (1.6)	0.353	1,091 (5.9)	877 (4.7)	0.051
Metiglinides n (%)	25 (0.1)	60 (0.1)	0.005	20 (0.1)	27 (0.1)	0.011
Metformin + metiglinid n (%)	380 (1.4)	560 (1.0)	0.035	327 (1.8)	289 (1.6)	0.016
Glitazones n (%)	122 (0.4)	199 (0.3)	0.014	100 (0.5)	97 (0.5)	0.002
Acarbose n (%)	774 (2.8)	2830 (5.0)	0.114	674 (3.6)	698 (3.8)	0.007
Insulin n (%)	11,219 (40.1)	3,042 (5.3)	0.911	2,932 (15.8)	2,555 (13.7)	0.057
Short acting insulin (Human/analog) n (%)	8,052 (28.8)	1,245 (2.2)	0.790	1,414 (7.6)	1,202 (6.5)	0.045
Intermediate insulin (human basal) n (%)	5,140 (18.4)	1,575 (2.8)	0.525	1,460 (7.9)	1,230 (6.6)	0.048
Long acting insulin (analog basal) n (%)	6,856 (24.5)	1,146 (2.0)	0.703	1,280 (6.9)	1,048 (5.6)	0.052
Premix insulin (human/analog) n (%)	1,704 (6.1)	455 (0.8)	0.293	573 (3.1)	426 (2.3)	0.049
CV risk treatment n (%)	25,696 (91.8)	51,214 (90.0)	0.066	16,860 (90.7)	16,481 (88.7)	0.067
Low dose Aspirin n (%)	9,074 (32.4)	16,813 (29.5)	0.063	5,444 (29.3)	5,405 (29.1)	0.005
Statin n (%)	14,339 (51.2)	27,431 (48.2)	0.061	8,916 (48.0)	8,823 (47.5)	0.010
Antihypertensives n (%)	24,539 (87.7)	48,664 (85.5)	0.065	16,018 (86.2)	15,687 (84.4)	0.050
ACEi n (%)	16,300 (58.3)	33,242 (58.4)	0.003	10,645 (57.3)	10,631 (57.2)	0.002
ARB n (%)	8,405 (30.0)	15,505 (27.2)	0.062	5,304 (28.5)	5,254 (28.3)	0.006
Dihydropyridine CCB n (%)	6,140 (21.9)	13,067 (23.0)	0.024	3,964 (21.3)	4,041 (21.7)	0.010
Non-dihydropyridine CCB n (%)	368 (1.3)	795 (1.4)	0.007	228 (1.2)	210 (1.1)	0.009

Beta blockers n (%)	15,648 (55.9)	29,807 (52.4)	0.072	9,885 (53.2)	9,805 (52.8)	0.009
Thiazides n (%)	177 (0.6)	409 (0.7)	0.010	107 (0.6)	105 (0.6)	0.001
Loop diuretics n (%)	5,472 (19.6)	10,220 (18.0)	0.041	3,046 (16.4)	3,041 (16.4)	0.001
Aldosterone antagonist n (%)	2,096 (7.5)	3,550 (6.2)	0.050	1,200 (6.5)	1,150 (6.2)	0.011
Digoxin n (%)	452 (1.6)	1,203 (2.1)	0.037	300 (1.6)	322 (1.7)	0.009
Digitoxin n (%)	186 (0.7)	639 (1.1)	0.049	126 (0.7)	109 (0.6)	0.012
Amiodarone n (%)	275 (1.0)	674 (1.2)	0.019	182 (1.0)	170 (0.9)	0.007
Warfarin n (%)	638 (2.3)	1,391 (2.4)	0.011	404 (2.2)	417 (2.2)	0.005
P2Y12 receptor antagonists n (%)	2,755 (9.8)	5,910 (10.4)	0.018	1,680 (9.0)	1,738 (9.4)	0.011
Factor X _A inhibitor n (%)	328 (1.2)	730 (1.3)	0.010	228 (1.2)	215 (1.2)	0.006
Direct thrombin inhibitor n (%)	129 (0.5)	263 (0.5)	<0.001	92 (0.5)	97 (0.5)	0.004
Other antiplatelets n (%)	60 (0.2)	144 (0.3)	0.008	40 (0.2)	44 (0.2)	0.005
Corticosteroids n (%)	1,236 (4.4)	2,794 (4.9)	0.023	845 (4.5)	851 (4.6)	0.002
Weight loss medication n (%)	<10 (0.0)	<10 (0.0)	0.009	<10 (0.0)	<10 (0.0)	<0.001

ata include some demographic parameters, significant co-morbidities as well as anti-diabetic and cardiovascular medications.

=angiotensin-converting enzyme inhibitors, ARB=angiotensin-II receptor blockers, CCB=calcium channel blockers, CV = vascular,

SMD=standardized mean difference